Meteorin-like enhances aged muscle regeneration

Pathologies associated with sarcopenia include decline in muscular strength, lean mass and regenerative capacity. Despite the substantial impact on quality of life, no pharmacological therapeutics are available to counteract the decline of functional capacity, loss of independence and resilience. Evidence suggests immune-secreted cytokines can improve muscle regeneration; a strategy which we leverage in this study by rescuing the age-related deficiency in Meteorin-like (Metrnl) through several in vivo add-back models. Notably, a direct, intramuscular peptide injection of recombinant METRNL was sufficient to improve muscle regeneration in aging. This RNAseq dataset substantiates that rMETRNL treatment via intramuscular injections is sufficient to rejuvenate the aged muscle regenerating transcriptome to that of young controls. Overall design: RNA-seq comparing muscle cell suspension gene expressions between young control, old control and old Meteorin-like treated mouse muscle 4 days following injury.